You are here:Home-Inhibitors & Agonists-Antibiotics and Antivirals-CMV

Request The Product List ofCMV CMV

Cytomegalovirus (CMV) is a betaherpesvirus with a 50 to 90% prevalence frequency in the adult human population. It is an opportunistic pathogen controlled largely by the immune system, especially cell-mediated immunity. Clinically serious disease occurs primarily in three situations involving deficient immune systems.

Treatment of HCMV disease is limited to relatively toxic drugs with that target viral DNA synthesis. The most commonly used HCMV drug, ganciclovir, is a nucleoside prodrug phosphorylated by the viral UL97 kinase to the nucleotide analog form and is selectively incorporated into progeny DNA by the HCMV UL54-encoded DNA polymerase. Foscarnet is a pyrophosphate analog. Effective concentrations of foscarnet are much higher than that of ganciclovir. Both of these drugs are nephrotoxic; ganciclovir also causes neutropenia and is teratogenic. Cidofovir is a nucleoside phosphonate that is severely renal toxic.

 

Cat. No. Product Name CAS No. Information
PC-61945

Tomeglovir

233254-24-5

Tomeglovir (BAY 384766) is a potent, highly selective, nonnucleoside inhibitor of cytomegalovirus (CMV) replication; selectively inhibits not only HCMV strains, including ganciclovir-resistant clinical isolates, but also a number of monkey and rodent cytomegaloviruses.

CMV Infection

Phase 2 Discontinued

PC-35123

CFI02

273735-28-7 CFI02 (CFI-02) is a specific inhibitor of human cytomegalovirus (HCMV) glycoprotein B-mediated fusion with IC50 of 40 nM against laboratory adapted HCMV strain AD169; reduces HCMV yield by >3 logs at 1 uM, and shows no inhibitory activity against closely related betaherpesviruses (including MCMV, simian CMV, and RCMV) (IC50>20 uM) as well as cytotoxic effect (CC50>50 uM).
PC-62054

Brincidofovir

444805-28-1 Brincidofovir (CMX 001;Cidofovir HDP) is a lipid conjugate of the acyclic nucleotide phosphonate, cidofovir that shows activity against all five families of dsDNA viruses that cause human morbidity and mortality, including orthopoxviruses such as variola virus, the cause of human smallpox; has a number of advantages for treatment of smallpox in an emergency including greater potency in vitro against all dsDNA viruses that cause human disease, a high genetic barrier to resistance, convenient oral administration as a tablet or liquid, and no evidence to date of nephrotoxicity in either animals or humans.

CMV Infection

Phase 3 Clinical

PC-61947

GW 275175X

217950-62-4 GW 275175X is a derivative of BDCRB that displays anti-HCMV activity by inhibition of viral DNA maturation; shows antiviral efficacy against AD169 laboratory strain in DNA hybridization assays with IC50 of 0.7 uM, against 10 clinically relevant HCMV isolates with IC50 of 0.16-2.21 uM, and little or no activity against HSV-1, HSV-2 and varicella zoster virus; inhibits viral DNA maturation in a dose-dependent fashion.
PC-61946

BDCRB

142356-43-2 BDCRB (GW 275175) is a potent and selective inhibitor of human CMV replication by blocking the processing and maturation of viral DNA.
PC-45260

Cidofovir dihydrate

149394-66-1 The prodrug of cidofovir diphosphate that inhibits cytomegalovirus (CMV) viral replication by selectively inhibiting viral DNA polymerases; also incorporates itself into viral DNA hence inhibiting viral DNA synthesis during reproduction.

CMV Infection

Approved

PC-45259

Cidofovir

113852-37-2 The prodrug of cidofovir diphosphate that inhibits cytomegalovirus (CMV) viral replication by selectively inhibiting viral DNA polymerases; also incorporates itself into viral DNA hence inhibiting viral DNA synthesis during reproduction.

CMV Infection

Approved

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com